The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes.

Journal of managed care pharmacy : JMCP

Volumn 13, Issue 9 Suppl C, 2007, Pages

  Triplitt, Curtis ^a   McGill, Janet B ^a   Porte Jr , Daniel ^a   Conner, Christopher S ^a  

^a Texas Diabetes Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; INCRETIN;

CLINICAL TRIAL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVALENCE; REVIEW; TREATMENT OUTCOME; UNITED STATES;

ANTILIPEMIC AGENTS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; INCRETINS; PREVALENCE; TREATMENT OUTCOME; UNITED STATES;

EID: 41949084607     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)